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ABSTRACT

Macrocyclic antibiotics having ring Structures with at least
10 members act as Separation agents in crystallization,
precipitation, filtration, electrophoresis and chromatogra
phy. The macrocyclic antibiotics include anSamacrollides,
macrollides, marocyclic peptides, polyenes and derivatives
thereof. The proceSS has been found to be especially advan
tageous for Separation of optical isomers by electrophoresis
and chromatography.
10 Claims, 4 Drawing Sheets
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1
MACROCYCLIC ANTIBIOTICS AS
SEPARATION AGENTS

This application is a divisional of U.S. Ser. No. 08/532,
581 filed Sep. 29, 1995 now U.S. Pat. No. 5,626,727 on May
6, 1997; which, in turn, was an application pursuant to 35
USC 371 of PCT/US95/02071, filed Feb. 17, 1995, which,

in turn, is a continuation-in-part of U.S. Ser. No. 08/198,409,
filed Feb. 22, 1994, now abandoned.

This invention relates to a novel use of a macrocyclic
antibiotic and, more specifically, to the novel use of mac
rocyclic antibiotics to effect the Separation of a particular

compound from a fluid (i.e. gas or liquid). The macrocyclic
antibiotics of the present invention are especially useful as
a Stationary phase or as a mobile phase or Solution additive
in chromatography and electrophoresis for the Separation of
isomers, particularly optical isomers.
Antibiotics are a class of chemical compounds which are
produced by microorganisms, and capable, in a dilute
Solution, of inhibiting the growth of or destroying bacteria
and other microorganisms. Today, Some antibiotics are also
produced Synthetically. Chemically, antibiotics have a wide
variety of Structures and belong to various groups of com
pounds. Generally, antibiotics have three names, a chemical
name, a generic name and a tradename. For example,
tetracycline, generic name, is 4-dimethylamino-1,4,4a,5.5a,
6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl
1,11-dioxo-2-naphthocenecarboxamide, chemical name,
and is Sold under the tradenames Panmycin and Tetracyn.
The generic name is generally preferred and will be used in
the Specification and claims.
A variety of methods are available for the separation of
an individual component or chemical compound from fluids.
Among these methods are distillation, extraction,
crystallization, precipitation, filtration, electrophoresis and
various chromatographic techniques.
Crystallization and precipitation are often batch opera
tions which entail the addition of an agent to assist in the
removal of a component from the fluid as a Solid particle.
Generally, the Solid particles fall to the bottom or rise to the
top of the fluid.
Filtration can be either a batch or continuous process and
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includes reverse Osmosis or ultrafiltration and membrane

permeation. Such processes entail the Selective Separation of
components from a fluid due to the porosity of a filter. The

from the other enantiomer. It is therefore essential to be able
45

filter itself can be either a fluid or a solid.

Chromatography, which also operates in either a batch or
continuous mode, includes liquid chromatography, gas
chromatography, paper chromatography and thin-layer chro
matography. Chromatography is based on the differential
distribution of components between two phases, a mobile
phase and a Stationary phase. The mobile phase is typically
a gas or liquid while the Stationary phase is typically a Solid
or a liquid. Separation occurs because the mobile phase is
brought into contact with the Stationary phase and caused to
move past the Stationary phase. Components in the mobile
phase travel in the mobile phase at different rates depending
on their affinity for the two phases.
Electrophoresis involves the motion of electrically
charged particles in an electric field and comprises applying
an electric field to a Solution Such that components in the
solution move by means of the electric field. Electrophoresis
can be done with free Solutions in the presence of a gel, or
in the presence of a chromatographic-like Stationary phase

(the later is Some times referred to as
electrochromatography). There are a variety of electrophore
sis techniques. Electrophbresis can be performed in capil

2
laries (capillary electrophoresis, CE), in tubes, in slabs, etc.
Electrophoresis is typically only a batch process.
A number of these Separation processes employ a chemi
cal agent to assist in the Separation of the compound which
has been targeted for Separation. Typically, these chemical
agents, i.e. Separation agents, are either added to the fluid
phase So as to combine with the targeted compound and
assist or effect the Separation of the targeted compound, or
the Separation agent is fixed to a Stationary phase and
interacts with the targeted compound as it passes by the fixed
Separation agent thereby assisting or effecting the Separation
of the targeted compound.
When using crystallization or precipitation, the Separa
tion agent is typically added to the fluid Such that it com
bines with the compound targeted for Separation and causes
precipitation or crystallization of a complex of the targeted
compound and the Separation agent. In a filtration process,
the Separation agents typically make up part of the filter by
being either affixed to the filter or contained in the liquid
which acts as the filter. In the fields of chromatography and
electrophoresis, the Separation agent is either attached to a
Solid Support or dissolved in Solution.
In the past, a number of different materials have been
used as Separation agents for chromatography and electro
phoresis. Separation agents which have been affixed to the
Stationary phase in the field of chromatography include
amino acids, derivatives of amino acids, proteins,
cyclodextrins, derivatives of cyclodextrins and derivatives
of linear or branched carbohydrates. In the field of
electrophoresis, cyclodextrins and their derivatives have
been used as Separation agents with a wall immobilized
chiral stationary phase. More often in the field of
electrophoresis, the cyclodextrin is dissolved in free Solution
as are derivatives of cyclodextrin, amino acids, and Soluble
carbohydrates. The uses of Separation agents in
crystallization, precipitation, filtration, electrophoresis and
chromatography is well-known and conventional.
The use of various Separation agents and Separation
processes have been employed to Separate optical isomers.
The configuration of an optical isomer or chiral molecule
generally determines its biological and pharmacological
activity and effectiveness. It is not uncommon for one
enantiomer of a chiral molecule to have a different activity
to Separate and isolate the one enantiomer from the other.
Separation agents used to Separate optical isomers are often
referred to as chiral Selectors.

50

55

60

65

It has now been discovered that macrocyclic antibiotics
can be used as Separation agents in a wide variety of
Separation processes including crystallization, precipitation,
filtration, chromatography and electrophoresis. In fact, in
chromatography and electrophoresis processes, it has been
found that the macrocyclic antibiotic of the present inven
tion can Separate certain optical isomers which were here
tofore unable to be separated using known Separation agents.
It is both Surprising and unexpected that a macrocyclic
antibiotic works in Such a wide variety of Separation pro
ceSSes because these macrocyclic antibiotics are So large.
Heretofore only Small antibiotics have been Suggested for
use as a separation agent, see U.S. Pat. No. 5,194,133 issued
Mar. 10, 1993. The 133 patent does not disclose the use of
antibiotics for Separation of optical isomers.
It has been found that the macrocyclic antibiotic of the
present invention can be used both as a Stationary phase and
as a mobile phase or Solution additive for chromatography
and electrophoresis. Specifically, it has been found that the
macrocyclic antibiotic works as a Stationary phase in chro

5,874,005
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more than one macrocyclic ring, e.g. Vancomycin. Good
results have been found with a macrocyclic antibiotic having
from 1 to 4 macrocyclic rings.
It is not completely understood why the macrocyclic
antibiotic of the present invention works as a separation
agent. It is thought that, with respect to the Separation of
optical isomers, the enantioSeparation is made possible by a

3
matography and capillary electrophoresis and as a mobile
phase or Solution additive in capillary electrophoresis, thin
layer chromatography, and liquid chromatography. It has
also been found that the macrocyclic antibiotic of the present
invention when used as a Stationary phase in chromatogra
phy is Stable in both normal phase and reverse phase modes
of operation. Furthermore, it appears that the Selectivity of
the Stationary phase is different between the two chromato
graphic modes. Hence, the recognition mechanism in the
reverse phase is not the same as the recognition mechanism
in the normal phase. This phenomenon has been found in its
enantioSelectivity and its chiral recognition mechanism in
both the normal and reverse phases for chromatography.
The macrocyclic antibiotic of the present invention,
when used as a chiral Selector in a Stationary phase, has been
found to have a greater Stability and a higher capacity than
the prior art protein based Stationary phases. Unlike proteins,
macrocyclic antibiotics are not denatured or irreversibly
changed in enantioselectivity when used in normal phase

combination of several different mechanisms which allow

15

mechanisms available and because the areas on the macro

mode.

It has also been found that closely related macrocyclic
antibiotics when used as chiral Selectors have Somewhat

similar but not identical selectivity. This means that if one
macrocyclic antibiotic gives a partial Separation then there is
a very good chance that a closely related macrocyclic
antibiotic will give a baseline Separation under very similar
and often identical operating conditions.

25

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the resolution of bromacil, devrinol and
coumachlor enantiomers on a HPLC column in reverse

phase using Vancomycin bonded to a Silica gel,

FIG. 2 illustrates the resolution of N-(3,5-dinitrobenzoyl)
-alpha-methylbenzylamine and 3-2-(2-bromacetamide)
acetamide-PROXYL enantiomers on a HPLC column in

normal phase using Vancomycin bonded to a Silica gel;
FIG. 3 illustrates the effect of an organic modifier on the
Separation of 5-methyl-5-phenolhydantoin enantiomer on a
HPLC column in reverse phase using Vancomycin bonded to
a Silica gel,
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FIGS. 4A, 4B and 4C illustrate the effect on resolution of

increased analyte on a HPLC column in reverse phase using
Vancomycin bonded to Silica gel, and
FIG. 5 illustrates the effect on resolution by adjusting the
Solvent, polar verSuS non-polar Solvents, on a HPLC column
in reverse phase using Vancomycin bonded to Silica gel.
FIG. 6 illustrates a schematic of a macrocyclic antibiotic
bonded to a Support; and
FIG. 7 illustrates a foam Separation apparatus used to
Separate and enrich enantiomers.
The macrocyclic antibiotic of the present invention is an
antibiotic which has at least one macrocyclic ring structure.
The term macrocyclic ring Structure as used herein means
that the ring Structure contains at least about 10 members
and more preferably at least about 15 members. The term
member as used herein means a single atom. For example,
a benzene ring is a six-membered ring while anthracene has
three rings, each of which is a six-membered ring. Neither
benzene nor anthracene has a macrocyclic ring. On the other
hand, Vancomycin, which is a macrocyclic antibiotic of the
present invention, has ten rings, five of which are Six
membered aromatic rings and not macrocyclic; two non
aromatic Six-membered rings which are also not macrocy
clic; and three rings with more than ten members which are
macrocyclic rings in accordance with the present invention.
The macrocyclic antibiotic of the present invention can have

the macrocyclic antibiotic to form a complex with a targeted
component. These mechanisms include complexation,
charge-charge interactions, hydrogen bonding, inclusion in a
hydrophobic pocket, dipole Stacking, Steric interaction or
combinations thereof. While all other chiral stationary
phases avail themselves of the same types of interactions, a
plurality of these mechanisms is not available in a single
chiral Selector and in relatively close proximity to one
another. The plurality of interaction mechanisms of the
present invention is made possible because the Selectors of
the present invention have more than one of these interaction

45

cyclic antibiotic where these interaction mechanisms are
available are in close proximity to one another.
AS is known to those of skill in the art, different Separation
agents have different degrees of effectiveness in Separating
components. That holds true for the macrocyclic antibiotics
of the present invention. AS is shown in the following
examples, certain macrocyclic antibiotics are more effective
at Separating components than other macrocyclic antibiotics.
Derivatives of the macrocyclic antibiotic of the present
invention can also be used as Separation agents in accor
dance with the present invention So long as the interaction
mechanisms of the macrocyclic antibiotic are not destroyed.
It has been found that derivatization of the macrocyclic
antibiotic changes its selectivity. Derivatization as used in
the Specification and claims means not only the addition of
chemical components to the macrocyclic antibiotic but also
derivatization where a portion of the macrocyclic antibiotic
has been removed. Where a portion of the macrocyclic
antibiotic has been removed, at least one of the macrocyclic
ring Structures must remain intact to allow the macrocyclic
antibiotic dreivative to function as a Separation agent. For
instance, it is known that when certain macrocyclic antibi
otics are bonded to a Support matrix that a portion of the
macrocyclic antibiotic is lost during the chmeical reaction.
It is also known that there are methods which can be

employed in order to prevent the loSS of those portions of the
macrocyclic antibiotic which are lost during the bonding
reaction.
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Polymers of macrocyclic antibiotics of the present inven
tion can also be used as Separation agents in accordance with
the present invention.
The term macrocyclic antibiotic as used in the Specifica
tion and claims means not only the macrocyclic antibiotic
itself, but also derivatives of macrocyclic antibiotic as
defined above and polymers of macrocyclic antibiotic.
Polymers of the macrocyclic antibiotic of the present
invention can also be used as Separation agents in accor
dance with the present invention.
Likewise, it has been found that the macrocyclic antibi
otic of the present invention can be chemically bonded to a
Support and function as a separation agent. In bonding the
macrocyclic antibiotic of the present invention, Some of the
Structure of the macrocyclic antibiotic can be changed So
long as the interaction mechanisms of the macrocyclic
antibiotic are not destroyed.
Unlike other classes of Separation agents, macrocyclic
antibiotics comprise a large variety of Structural types

5,874,005
S
including macrocyclic polyene-polyols, ansa compounds

(e.g. aliphatic bridged naphthohydroquinones), macrocyclic
glycopeptides, peptides, peptide-heterocycle conjugates,
and So forth. In general, these compounds have molecular
weights greater than 600 but less than 2,500 Daltons. There
are acidic, basic and neutral types. Some cyclic antibiotics
absorb strongly in the UV and visible spectral regions while
others are fairly transparent.
Suitable macrocyclic antibiotics of the present invention
may be generally classified by their Similarity of chemical
Structure into the groups of: ansamacrollides, macrodites,
macrocyclic peptides, which include glycopeptides, and
polyenes. This list is not exhaustive and there are other
antibiotics wherein the antibiotic has at least one macrocy
clic ring which does not fit into one of these four categories.
The preferred antibiotics are Selected from the group of
anSamacrollides and macrocyclic peptides, especially glyco
peptides.
Ansamacrollides are a family of antibioticS characterized
by an aliphatic ansa bridge which connects two non-adjacent
positions on an aromatic nucleus. Ansamacrollides are gen
erally divided into two groups based on their aromatic
nucleus. One group contains a naphthoguinone and the other
a benzoquinone nucleus. The naphthoguinoid ansamycins
comprise the majority of the known anSamacrollides. Naph
thoguinoid ansamycins which are useful in the present
invention include Streptovaricins, rifamycins, tolypomycins,
halomicins, and naphthomycin. The benzoquinoid anSamac
rollides which are useful in the present invention include
geldanamycin and maytansinoids. The preferred anSamac
rollide is rifamycin and especially rifamycin B.
Macrollides are a class of antibiotics having a macrocyclic
ring forming the aglycone often as a 12-, 14- or
16-membered ring. Macrollides which are useful in the
present invention include chalcomycin, methymycin,
neomethymycin, erythromycin, megalomicin, picromycin,
narbomycin, oleandomycin, triacetyloleandomycin,
carbomycin, Spiramycin, and tylosin.
Macrocyclic peptides that are useful in the present inven
tion include SporideSmollides, capreomycin, ristomycin,

cyclosporins, tyrocidine, trioStins, gramicidins (gramicidin
5), tyrocidines, polymyxins, bacitracins, octapeptins,

actinomycins, etamycins, Vernamycins, enniatins,
Valinomycin, thiostrepton, teichomycin avoparcin, acta
planins and Vancomycin. The preferred macrocyclic pep
tides are glycopeptides, and more especially teichomycin
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(Z)-4 decanoic acid
8-methylnonanoic acid

A-3

n-decanoic acid

A-4
A-5

8-methyldecanoic acid
9-methyldecanoic acid

It is also to be understood that avoparcin includes alpha
avoparcin and beta-avoparcin. Further, it is to be understood
that actaplanins include the various types of actaplanins Such
S.

aOSC

B
B

rhamnosylglucose
glucose

aOSC
aOSC

B
C

mannosylglucose
rhamnosylglucose

H
H

G

glucose

H

Other antibiotics which do not fall into one of the four

general categories listed above, but have a macrocyclic
Structure and are useful in the present invention include
aplasmomycin, boromycin, enterobactin and bebeerine.
The most preferred macrocyclic antibiotics for use in the
present invention are Vancomycin, rifamycin, teicoplanin,
avoparcin, and thiostrepton. Of the various rifamycins, rifa
mycin B is most preferred. Vancomycin is an amphoteric
glycopeptide produced by the bacteria Streptomycin Orien
tallis. Rifamycin B is one of the most common members of
the family of rifamycin antibiotics and is obtained from the
bacteria Nocardia mediterranei. Thiostrepton is obtained
from the micro-organism Streptomyces azureus. Teichomy
cin is produced by the bacteria Actinoplanes teichomyceti
The macrocyclic antibiotics of the present invention can
be obtained from any conventional Source and are in many
cases commercially available. Suitable derivatives of mac
rocyclic antibiotics for use in the present invention are made
in any conventional manner using conventional reactants.
Suitable derivatives include hydroxypropyl derivatives
made with propylene oxide, acetyl derivatives made with

acetic anhydride, (R)- or (S)-naphthylethylisocyanate

The preferred glycopeptides have three (3) or four (4)

A-1
A-2

R

CS.

Thiostrepton is also a preferred peptide.

Teichomycin

R
mannosylglucose

Polyenes have a large lactone ring which contains 3 to 7
double bonds. The preferred polyenes are amphotericin
amphotericin B), candicidin, candidin, dermostatin, fun
gichromin and nyStatin.

(teicoplanin), ristomycin, avoparcin, and Vancomycin.

fused rings. There are different numbers and types of Sugars
attached to the aglycone. Such preferred glycopeptides hav
ing these 3 or 4 fused rings include Vancomycin,
teichomycin, ristomycin, avoparcin and actaplanins. It is to
be understood that teichomycin includes the different teicho
mycins Such as:

actaplanin
A.

60
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derivatives, 3,5-dimethylphenylisocyanate derivatives, 2,6dimethylphenylisocyanate derivatives, as well as others.
Polymers of the macrocyclic antibiotic which can be used
in the present invention include homopolymers, derived
from a Single monomer, or mixed polymers, derived from
more than one monomer. Such polymers are made in a
conventional manner using conventional equipment.
Typically, a crosslinking agent is used to chemically bond
one macrocyclic antibiotic to another.
In Stationary phase application, the macrocyclic antibiotic
of the present invention is affixed to a Support in a conven
tional manner. Suitably, the macrocyclic antibiotic of the
present invention is affixed to a Support by either coating a
Support or chemically bonding the macrocyclic antibiotic to
the Support.
The coating of the macrocyclic antibiotic of the present
invention on a Support is done in a conventional manner
using conventional equipment. One Suitable means for coat
ing Silica gel entails using macroporous Spherical Silica gel
particles and Silanizing these particles with a large excess of
dichlorodiphenyl Silane and triethylamine at refluxing tem
perature in toluene. The Silanized Silica gel is then coated
with the macrocyclic antibiotic. The coated Silica gel is used
in a conventional column. In the case of coating a Silica gel,
polymers or copolymers of the macrocyclic antibiotic are
preferred as they are not easily removed during Separation
procedures.
The macrocyclic antibiotic is chemically bonded to a
Support using conventional bonding chemistry, So long as it
does not destroy the interaction mechanisms of the macro
cyclic antibiotic which yields the Separation mechanism of

5,874,005
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the present invention. The chemical bond between the
Support and the macrocyclic antibiotic forms a leash, bridge
or spacer between the Support and the macrocyclic antibi
otic. The leash must be long enough So that the macrocyclic
antibiotic is able to function as a separation agent, yet not So
long as to dominate the Separation. The order of reaction,
e.g. Support to then Support-leash to macrocyclic antibiotic,
will be dependent upon the chemistry of the Support, leash
and macrocyclic antibiotic. FIG. 6 illustrates a Schematic of
macrocyclic antibiotic 10 bonded to support 12 by linkage
14.

Suitable Supports for making the Stationary phase in
accordance with the present invention include inorganic
materials. Such as Silica gel and alumina, Synthetic polymeric
materials. Such as polystyrenes, polyurethanes, polyvinyl
alcohol and polyamides, natural materials. Such as agarose,
cellulose, dextran and linear and branched amylose. A
preferred Support is Silica gel.
In the case of chemically bonding a macrocyclic antibiotic
to a Silica gel, Suitable bonding of the macrocyclic antibiotic
to the Support can be by way of a carboxylic acid terminated
organosilane, an amine terminated oxysilane, epoxy termi
nated organosilanes and isocyanated terminated organosi
lanes. Suitable carboxylic acid terminated organosilanes

include 10-(carbomethoxy)ethylmethyldichlorosilane and
2-(carbomethoxy)-ethyltrichlorosilane. Suitable amine ter

15
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minated organosilanes include 3-amino-propyldimethyl
ethoxysilane and 3-aminopropyltriethoxysilane. Suitable

2-10 times more.

epoxy terminated Silanes include (3-glycidoxypropyl) tri

methly loxysilane, 3-glycidoxypropyldimethylethoxysilane
and 3-glycidoxypropyltriethoxysilane. Suitable isocyanated
terminated organo Silane S include 3-isocyanato
propyltrie thoxy Silane
and
3-isocyanatopropyldimethylchlorosilane.
The linkage between the macrocyclic antibiotic and the

35

leash includes ether, thioether, amine, amide, carbamate,

urea, and hydrocarbon.
In order to form the Stationary phase in accordance with
the present invention using a carboxylic acid terminated or
an amine terminated organosilane, dry Silica is slurried with
dry toluene and a Solution of the organosilane in toluene is
added dropwise over a period of time and refluxed with the
toluene Silica gel Slurry. Refluxing is continued over a period
of time at about 110°C. An amount of macrocyclic antibiotic
is added along with an appropriate carbodiimide dehydrating
agent. After allowing the mixture to react for a period of
time, the Stationary phase is filtered and washed.
In order to bond the macrocyclic antibiotic of the present
invention to a Silica gel and an isocyanate terminated
organosilane, the macrocyclic antibiotic is reacted with a 2
or 3 molar excess of the organosilane in an anhydrous DMF.
The reaction product is then added to a dry DMF slurry of
Silica gel wherein the weight ratio of modified macrocyclic
antibiotic to Silica gel is about 1:2. The Solution is stirred and
allowed to react for 20 hours at about 105 C. Subsequently,
the reaction product is filtered and washed.
In order to form a Stationary phase using the macrocyclic
antibiotic of the present invention, Silica gel and an epoxy
terminated organosilane are reacted in toluene in a conven
tional manner, see for example U.S. Pat. No. 4,539,399.
Other Suitable bonding chemistries between the Silica gel
or glass bead and the macrocyclic antibiotic of the present
invention include making an O-aminopropyl Silanized Silica
gel and then using a glutaraldehyde to attach an amino group
from the macrocyclic antibiotic to the Silanized Silica gel.
Such a process works where the macrocyclic antibiotic has
an amino group.

In the case of a natural Support Such as agarose, cellulose,
dextran or linear and branched amylose, the macrocyclic
antibiotic is bonded to the Support in a conventional manner
using conventional equipment. See, for example, "Affinity
Chromatography”, Chemical and Engineering NeWS, Aug.
26, 1985, pages 17-32.
The Stationary phase employing the macrocyclic antibi
otic of the present invention also includes encapsulation.
Encapsulation of the macrocyclic antibiotic of the present
invention is accomplished using a conventional process in a
conventional manner to build a porous polymer cage around
the macrocyclic antibiotic. Such porous polymer cages are
formed as beads and are then used in columns. The porous
cage allows the flow of material through the cage while
preventing the escape of the macrocyclic antibiotic. In this
way, the macrocyclic antibiotic of the present invention is
able to function as a separation agent.
The macrocyclic antibiotic of the present invention is
used in a conventional manner in a conventional Separation
process Such as crystallization, precipitation, filtration, elec
trophoresis or chromatography.
In crystallization and precipitation, it is added as a sepa
ration agent to fluid in an amount effective to cause precipi
tation or crystallization of the targeted component, prefer
ably in an amount greater than the amount of component in
Said fluid targeted for Separation, more preferably about
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In a filtration process, the macrocyclic antibiotic is affixed
to a Solid Support or included as a component in the liquid
filter. The macrocyclic antibiotic is used in the filtration
process in a conventional manner with conventional equip
ment. The amount of macrocyclic antibiotic used in the filter
is an amount effective to Separate the targeted component.
In the processes of electrophoresis and chromatography,
the macrocyclic antibiotic of the present invention is used in
a conventional manner with conventional equipment as a
mobile phase additive or affixed to a Support.
These and other aspects of the present invention may be
more fully understood by reference to the following
examples.
EXAMPLE 1.

This example illustrates making a Stationary phase of
macrocyclic antibiotics in accordance with the present
45

invention.

50

cyclic antibiotic was dried in vacuo over P.O.s at 100° C. for
four hours. Dried macrocyclic antibiotic was then dissolved
(using a stirring bar) with 100 ml of Anhydrous N,Ndimethyl formamide (DMF) in a 500 ml, three-neck round

In order to make a Stationary phase, 1.0 g of the macro

55

60

bottom flask. The reaction was blanketed with dry N gas.
Dry N gas was introduced through one neck and initially
was allowed to Sweep through the apparatus and escaped
through the Second neck which also was fitted with a
thermometer using a Standard two neck adapter. The third
neck of the round bottom flask was equipped with a drop
ping funnel which had a pressure equalizing Side tube. The
flask was heated using a heating mantle. When the tempera
ture of the solution reached 90°-95 C., 520 ul of
3-isocyanatopropyltriethoxysilane which was dissolved in

20 ml of DMF was added dropwise (at the rate of 10–15
dropS/min.) while stirring the flask. After adding the reagent,
the reaction was stirred for 10 hours. These steps produced
a macrocyclic antibiotic-bonded-to-the-organosilane. Next,
65

3.5g of Silica gel (spherical, 5u, 100 A pore size) was dried
in vacuo at 100° C. over POs for four hours. The dried silica
gel was then added to the DMF solution of macrocyclic
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antibiotic-bonded-to-the-organosilane and Stirred and heated

ventional manner. The columns were made of StainleSS Steel

to 105 C. and allowed to react for 20-24 hours. The mixture

was then allowed to cool to room temperature, filtered and

and measured 25 cm in length and had an inside diameter of
0.44 cm. Either a Shimadzu LC 6A liquid chromatograph

washed with DMF, methanol, toluene, methanol, water and

with UV detection (254 nm) and a C-R3A chromatopac data

methanol.

Station or a Waters model 590 HPLC with a 745B data

module was used with the column to obtain the data reported
in Table II above. Each separation was carried out at a flow

This procedure was employed for each of the macrocyclic
antibiotics as listed in Table I below:

rate of 1.0 ml per minute and at room temperature (22 C.).

TABLE I
1O

Vancomycin
Streptomycin
Rifamycin B
3.5 dimethylphenyl-derivitized vancomycin
15

EXAMPLE 2

This example illustrates the use of various immobilized
macrocyclic antibiotics as Separation agents in a Stationary
phase. In this example, liquid chromatography was
employed as the Separation process to Separate optical
isomers. The data from this example are reported in Table II
below for running the column in reverse phase condition.

The columns were run in reverse phase in a conventional
manner using 5 ul of a dilute Solution obtained from a
solution of 10 ug dissolved in 1 ml concentrate. The chiral
Stationary phases were prepared in accordance with
Example 1 above.
The Separation factor, alpha, was a measurement of the
Separation between the eluted peaks. The greater the Sepa
ration between the peaks, the greater the value of alpha.
Mathematically, alpha is defined as the ratio of corrected
retention times of the two peaks being compared, i.e.
where t'=corrected retention time, t=uncorrected time and

to-retention time of an unretained compound. Traditionally,
the longest retained peak time t is put in the numerator So

TABLE II
Compounds

kb

C.

1)
2)

Coumachlor
Warfarin

3.27 2.O
1.98
70

3)
4)

5)

Devrinol
5-Methyl-5phenylhydantoin
Proglumide

6)

C-(1-Aminoethyl)-4-

Mobile Phase
Of90
Of90

pH

Column

4.1
7.0

Van
Van

2.27

1.44

Of90

4.1

Van

140
O38
O.24
1.17
1.18
O.39

62
1.41
36
140
1.75
1.30

Of90
Of90
Of90
Of90
Of90
Of90

4.1
7.0
4.1
7.0
4.1
7.0

Van
Van
Van
Van
Van
Van

1.58 1.25
O.67 .21
O.38 .21
O32 1.21

Of90
Of90
Of90
Of90

7.0
7.0
7.0
7.0

Van
Van
Rif
Van

O84 120
O31 120

Of90
Of90

7.0
4.

Van
Van

O.79 1.15
O.47 1.15

Of90
Of90

7.0
4.

Van

0.68 1.15
3.29 1.15

Of90
Of90

7.0
4.

Van
Van

3.OO 1.15
1.55 1.15

Of90
Of90

4.
4.

Van
Van

22.0
15
6.17 114
O.78 1.14

Of90
O196
Of90

7.0
4.
7.0

Thio
Van
Van

Dansyl-serine
Indapamide

2.09 112
1.35 1.12

Of90
Of90

4.
7.0

Van
Van

24)

Benzoin methyl ester

O.80 111

Of90

7.0

Van

25)

N-benzoyl-leucine

1.90 110

Of90

4.

Van

hydroxybenzyl
alcohol

7)
8)
9)
10)

Bendroflumethiazide
Bromacil
Idazoxan
5-Cyano-6-methoxy-3,4-

dihydro-2-pyridone
11)
12)

Pyridoglutethimide
N-carbamyl-D,L-

13)
14)

Aminoglutethimide
N-benzoylalanine

phenylalanine
methyl ester
15)
16)

Coumafuryl
Dansyl-C-amino-n-

butyric acid
17)
18)

Dansyl-aspartic acid
N-(3,5-dinitrobenzoyl)-

19)
20)
21)

Thioridazine
Dansyl-norleucine
5-(4-Hydroxyphenyl)-

phenylglycine
5-phenylhydantoin
22)
23)

The compounds in this table are listed in order of their C-values from highest to lowest.
This is the k of the first eluted enantiomer.

The mobile phase compositions indicated are the volume ratios of acetonitrile to 1%
triethylammonium acetate buffer.
The abbreviations for the column are as follows: Van = vancomycin bonded stationary
phase, Thio = Thiostrepton bonded stationary phase and Rif = rifamycin B bonded stationary
phase.
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In order to test the different chiral Stationary phases,
columns were packed with the Stationary phases in a con

that alpha will be greater than 1. An alpha value of 1 means

that there is no separation (the peaks co-elute).

5,874,005
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The capacity factor of the first eluted enantiomer, k, is the
ratio of the corrected retention time to the retention time of

TABLE IV-continued

an unretained compound, i.e. k=(t-to)/to
FIG. 1 shows the resolution of bromacil, devrinol and

coumachlor enantiomers in the reverse phase mode of the
Vancomycin bonded phase column. This run was conducted
using the apparatus and following the method of this
example. The mobile phase consisted of a 10/90 mix of
acetonitrile and 1% triethylammonium acetate buffer at a pH

k

C.

Rs

22
35
45

1.18
O.93
O.76

.75
57
.44

2.1
18
1.6

O.35
0.27
O.24
O.24
O.19

38
36
34
3O
32

1.5
1.O
1.O
O.9
O.7

O.51
O.39
O.38
O31
0.27
O.22

39
34
23
2O
.11
OO

1.5
1.3
1.O
O.8
O.7
O

5-Methyl-5-phenylhydantoin
O
5
22
35
45

of 7.

It should be noted that enantiomers of 5-cyano-6methoxy3,4-dihydro-2-pyridene have never been reported to
have been resolved using a chiral Stationary phase.
EXAMPLE 3

Temperature (C.)

N-Carbamyl-D.L-phenylalanine
O
5
15
22
35
45

15

This example illustrates the effect of pH on the separation
of coumachlor and deVrinol using a Vancomycin Stationary
phase as prepared in Example 1 above. The Separation
proceSS employed in this example was liquid chromatogra
phy. The mobile phase was the Same as in Example 2 above,
and the columns were run in the Same manner as Example
2 above. The results of this experiment are reported in Table

EXAMPLE 5

III below.
TABLE III

25

Coumachlor

Devrinol

pH

k

C.

Rs

k'

C.

Rs

7.6
6.2
5.5
4.5
3.6

1.OO
1.21
2.OO
3.00
1.65

1.69
1.64
1.60
1.64
2.42

1.6
2.1
2.7
4.1
3.9

1.15
1.16
1.36
1.46
1.19

18O
1.77
1.76
1.70
4.41

3.2
3.3
3.5
3.6
3.7

The values of k and alpha are determined in the same

35

This example illustrates the effect of flow rate on the
Separation of 3a,4,5,6-tetrahydroSuccinimidol 3,4acenaphthen-10-one. The Separation proceSS employed in
this example was liquid chromatography. A column was
packed with a Vancomycin Stationary phase as prepared in
Example 1 above and the mobile phase was a 50:50 (by
Volume) mix of isopropanol and hexane. Except for the fact
that the column was run on normal phase, the column was
run as in Example 2 above. As shown in Table V below, mass
transfer was minimized by lowering flow rate which
enhanced resolution, while having no effect on alpha. Apha
and Rs were determined in the same manner as Example 4
above.

manner as in Example 2 above. R=20t-t)/(wi+wal) where
w and we are the baseline peak widths of the first and
Second eluted peaks respectively.

TABLE V
40

EXAMPLE 4

This example illustrates the effect of temperature on the
Separation of proglumide, 5-methyl-5-phenylhydantoin, and
N-carbamyl-D,L-phenylalanine. The Separation process
employed in this example was liquid chromatography. A
Vancomycin Stationary phase as prepared in Example 1
above was employed. The mobile phase was the same and
the column was run in the same manner, reverse phase, as in
Example 2 above. The pH of the mobile phase was 4.1. The
results from this experiment are reported in Table IV below.
The k, alpha and R values are determined in the same
manner as in Example 3 above.
Table IV shows that lowering the separation temperature

increases the retention as well as the Selectivity (i.e. alpha
value). In most cases it also resulted in enhanced resolution
(R). This means that the gain in Selectivity (alpha) was not

Temperature (C.)

C.

Rs

50

55

1.33
1.33
1.31

2.27
2.11
1.87

3.6
3.3
2.4

Proglumide
O
5
15

Rs

O.SO
0.75
1.OO
1.50
2.OO

1.31
1.31
1.27
1.30
1.29

1.28
1.19
1.14
1.13
1.11

EXAMPLE 6

60

k

C.

45

completely offset by the loss in efficiency from the decrease
in mass transfer that often occurs at lower temperatures.
TABLE IV

Flow Rate ml/min
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This example illustrates the Separation obtained from
various racemic compounds using various columns as pre
pared in Example 1 above. The Separation proceSS employed
in this example was liquid chromatography. Except for
operating the columns in normal phase resolution, the com
pounds were Separated in the same manner as Example 2
above. The chromatographic data are reported in Table VI
below. Alpha and k were determined in the same manner as
Example 2 above.

FIG. 2 shows the resolution of N-(3,5-dinitrobenzoyl)alpha-methylbenzylamine and 3-2-(2-bromacetamido)
acetamide-PROXYL as reported in Table VI below.
It should be noted that the separation of 3-2-(2bromacetamido)acetamide-PROXYL has not been

achieved in any other chiral Stationary phases heretofore.
It should also be noted that separations were only
achieved with polar organic mobile phases for the last four
compounds in Table VI below.

5,874,005
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13
TABLE VI
kb

C.

Mobile Phase

Column

2.50

.67

50/50

Van

Mephobarbitol
Hexobarbital

O.58
O.75

62
.61

50/50
50/50

N-(3,5-dinitrobenzoyl)

O.82

36

50/50

Van
Van
Van

5.30
2.67

35
35

65/35
50/50

Thio
Van

2.OO

.33

10/90

Van

2.63

3O

50/50

Van
Van
Rif
Van
Van
Van
Van

Compounds

1)

5-Methyl-5-phenyl-

hydantoin
2)
3)

4)

C.-methylbenzylamine
5)
6)

Althiazide
1-Benzoyl-2-tert-butyl-3-

7)

N-(3,5-dinitrobenzoyl-C-

methyl-4-imidazolidinone
methylbenzylamine
8)

3-2-(2-Bromoacetamido)

acetamido-PROXYL

9)

Mephenytoin

1.64

3O

10/90

10)

Laudanosine

2.37

13

10/90

4.43

.08

40/60

11)

Oxprenolol

6.O7

13

495/5/2/1f

12)
13)

Alprenolol
Propranolol

6.O7
8.17

O5
.04

495/5/2/1f
495/5/2/1f

The compounds in this table are listed in order of their C-values from highest to lowest
(except for the last four compounds which use a different mobile phase).
This is the k of the first eluted enantiomer.

The mobile phase composition represents the volume ratio of isopropanol to hexane.
The abbreviations for the columns are as follows:

Van = Vancomycin bonded stationary phase, Thio = Thiostrepton bonded stationary phase and
Rif = rifamycin B bonded stationary phase.
This mobile phase composition represents the volume ratio of isopropanol/hexane?
acetonitrile.

These mobile phase compositions represent the volume ratios of acetonitrile/methanol/

glacial acetic acid/triethylamine.

EXAMPLE 7

This example illustrates the use of a derivatized Vanco
mycin as a Stationary phase to Separate Various compounds
using a liquid chromatography Separation process. The Sta
tionary phase used in this example was made in accordance
with Example 1 above. Except for the fact that the column
was operated in normal phase, the column was operated in
the same manner as in Example 2 above. Chromatographic
data for this experiment are reported in Table VII below.

35

acetonitrile modifier from 0 to 50% (by volume) caused the
concentrations between 50 and 95% (by volume), there is
retention and enantioselectivity to decrease. At acetonitrile

40

TABLE VII
Compounds

kb

C.

Mobile Phase

O.67
1.46

2.03
50

10/90
50/50

DMP-Van
DMP-Van 45

O.91

.45

10/90

DMP-Van

4) 1-Benzoyl-2-tert-butyl- 1.16 1.20
3-methyl-4-

50/50

DMP-Van

1) Mephobarbital
2) 3a,4,5,6-Tetrahydro-

succinimido-3,4-b
acenaphthen-10-one
3) Hexobarbital
imidazolidinone

5) Ftorafur
6) N,N'-Bis(O-methyl-

Column'

Hydroxyzine
Mephenytoin
Phensuximide
C-Carbethoxy-y-

3.65
3.47

25
1.15

50/50
10/90

DMP-Van 50
DMP-Van

O.29
1.31
3.11
O.7O

1.14
.09
1.09
1.03

10/90
15/35

DMP-Van
DMP-Van

10/90

DMP-Van 55

phenyl
Y-butyrolactone
11) Glutethimide

0.78

O3

10/90

DMP-Van

These compounds are listed in order of their C-values (from highest to
lowest).
This is the k of the first eluted enantiomer.
The mobile phase compositions listed indicate the volume ratios of isopro
panol to hexane.
The abbreviation DMP-Van stands for the 3,5-dimethylphenylcarbamate
derivatized vancomycin bonded CSP.
EXAMPLE 8

This example illustrates the effect of organic modifier
concentrations on the Separation of 5-methyl-5-

little enantioSelective retention and the analyte elutes near
retention increases and enantioselectivity returns.
FIG. 3 plots the reverse phase retention of the first eluted
and Second eluted enantiomers as a function of mobile phase
composition. FIG. 3 refers to the first eluted enantiomer
which is designated by a box while the second eluted
enantiomer is designated by a blackened circle. The column
was run in the same manner as in Example 2 above.
the dead volume of the column. In neat acetonitrile the

EXAMPLE 9

benzyl)sulfamide
7)
8)
9)
10)

phenolhydantoin enantiomers using a column packed with a
Vancomycin Stationary phase as prepared in Example 1
above. The separation process employed in this example was
liquid chromatography.
AS Shown in FIG. 3, increasing the concentration of

60

This example illustrates the effect of increasing the
amount of analyte to be separated using liquid chromatog
raphy as the Separation process. The Separation agent
employed in this example was a Vancomycin Stationary
phase made in accordance with Example 1 above.
FIGS. 4A, 4B and 4C illustrate the different chromato

grams for a mixture of 5-methyl-5-phenylhydantoin iso
mers. FIG. 4A illustrates a chromatogram for a 1 lug amount
of the analyte; FIG. 4B illustrates a chromatogram for 500
tug of the analyte; and FIG. 4C illustrates a chromatogram
for 1600 lug of the analyte. The column was run in the same
manner as in Example 2 above with a mobile phase of neat
acetonitrile.
EXAMPLE 10

65

This example illustrates the effect of adjusting the ratio of
polar and non-polar organic Solvents in a mobile phase with
respect to the Separation of compounds using liquid chro

5,874,005
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matography as the Separation process. In this case, the
organic Solvents were hexane and isopropanol and the

using 25 millimolar of rifamycin B in 40% 2-propanol, 60%
0.1M phosphate buffer at a pH of 7.

enantiomers which were resolved were from a mixture of

Apparent mobility, u(a), is determined by the following
formula: u(a)=(1)/(txE)=(lxL)/(txV) wherein V is the
applied voltage, l is the effective capillary length (to the
detector), L is the total capillary length, t is the migration

methylphenylhydantoin isomers. The column employed had
a Vancomycin Stationary phase as prepared in Example 1
above, and the column was run as in Example 2 above
except it was run in normal phase mode.
FIG. 5 illustrates the results from this experiment. In FIG.
5 the square illustrates the first elute and the blackened circle
the second elute of the enantiomers. It should be noted that
only a polar organic phase was able to Separate certain of the
mixtures using this column, See Specifically the last four
enantiomers in Table VI of Example 6.

time as measured from the Start of the run until detection,
and E is the electronic field.

Effective mobility, u(e), is determined by Subtracting the
mobility of a neutral particle, u(EOF), from the apparent
mobility, i.e. u(a)-u(EOF). Apparent mobility and effective
mobility are conventional measurements.
EXAMPLE 12

EXAMPLE 11

This example illustrates using rifamycin B to Separate
various compounds. The Separation proceSS employed in
this example was electrophoresis, a Stationary phase com
prising a fused Silica capillary having the macrocyclic
antibiotic, rifamycin B, dissolved in Solution for use in
capillary electrophoresis. The results of the example are
reported in Table VIII below.

15

This example illustrates the effect of the concentration of
rifamycin B as a separation agent using the Separation
process of electrophoresis. A column as taught in Example
11 above and the apparatus and method of Example 11
above were used for this example. Table IX below shows the
migration times, apparent mobilities, effective mobilities
and resolution of the enantiomers.
TABLE IX

TABLE VIII

Compound

Rs

time"

u(a)

u(e)

Terbutaline

3.1

62.5

5.8

1.8

Isoproterenol

2.3

63.4

5.7

1.8

Bamethan

1.9

60.1

6.O

21

Metaproterenol
Synephrine
Metanephrine

1.8
1.7
1.6

59.5
53.3
57.O

6.O
6.7
6.3

21
2.8
2.4

Salbutamol

1.5

59.5

6.O

21

Epinephrine
Norphenylephrine

1.5
1.5

62.1
54.6

5.8
6.6

1.9
2.7

+-Ephedrine(1S,2R) and 1R,2S)

1.4

52.1

6.9

3.0

Migration times are given in minutes.

15 mM Rifamycin B
25

A fused Silica capillary having a 50 um inside diameter,
375 um outside diameter, and 57.5 cm total length was
obtained from Quadrex Corporation of New Haven, Conn.
The capillaries were prepared by burning off the protective
coating to form a window, inserting into a capillary holder
and then conditioning the capillary with 0.5 normal potas
sium hydroxide.
A Quanta 4000 Capillary electrophoresis apparatus Sup
plied by Waters and equipped with a 254 nm lamp was used
for the tests. The distance to the detector in the capillary was

Compound

Rs time u(a)

u(e) Rs time u(a) u(e)

Terbutaline
Norphenylephrine
Metoprolol

1.1 37.8
O.S. 36.2
O.2 39.0

2.4
28
2.1

room temperature (22 C.).

Enantiomeric resolutions, migration times and apparent
and effective mobilities of the enantiomers were determined

1.5 41.7
O.7 39.6
0.3 42.2

8.6
9.1
8.5

Compound

Rs

time

Terbutaline

2.O

48.6

7.4

1.7

Norphenylephrine
Metoprolol

O.8
0.4

45.6
49.2

7.9
7.3

2.2
1.6

2.O
2.4
1.9

At(a)

Al(e)

The migration time is given in minutes while the apparent

mobility, u(a), and effective mobility, u(e), are reported in
40
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cm2.kV-1.min-1. All separations were done with a buffer of
70% 0.1M phosphate and 30% 2-propanol with a pH of 7 at
the indicated amounts of rifamycin B.
AS can be seen from Table IX above, increasing the
concentration of rifamycin B tends to increase the migration
times Somewhat as a result of Small decreases in electro

phoretic mobility. As shown in Table IX, this significantly
enhances the enantiomeric resolution.

50 cm (effective capillary length). All analyzed Samples

were dissolved in distilled water at about 1 mg/mL, filtered
with 0.45 um nylon filters, and introduced into the capillary
using electromigration injection for 5 Seconds at 5 kV. The
tests were run at a voltage of 8 kV and were carried out at

9.5
9.9
9.2

25 mM Rifamycin B

35

u(a) is the apparent mobility in cm kV' min'.
-1
u(e) is the effective mobility in cm kV' min'.

20 mM Rifamycin B

EXAMPLE 13
50

This example illustrates the effect of pH on rifamycin B
as a separation agent in electrophoresis. The apparatus and
method of Example 11 above was used in this example. All
separations were done using 25 mM rifamycin B in 70%
0.1M phosphate and 30% 2-propanol. The results of this
experiment are reported in Table X below.

TABLE X

pH 5.2

pH 6.0

pH 7.0

pH 8.0

pH 9.0

Compound

Rs time u(a)

u(e) Rs time u(a)

u(e) Rs time u(a)

u(e) Rs time u(a)

u(e) Rs time u(a) u(e)

Terbutaline

O.6 55.O

6.5

2.6

1.8 42.6

8.4

2.5

2.0 48.6

7.4

1.7

1.4 49.2

7.3

1.3

0.8 34.0

10.5

1.2

Norphenylephrine
Metoprolol

0.3 45.0
O.2 58.O

8.0
6.2

3.3
23

O.9 41.1
O.4 48.6

8.7
7.4

2.7
1.5

O.8 45.6
O.4 49.2

7.9
7.3

2.2
16

O.4 46.2
O.3 37.4

7.8
9.6

1.6
1.5

0.0 34.8
0.0 32.8

10.3
11.0

0.5
1.3

5,874,005
17

18

The effect of pH on both migration time and enantiomeric
resolution is more complicated with rifamycin B than with
other Separation agents Such as cyclodextrin. This is because
rifamycin B has ionizable functional groups. Therefore, pH
not only affects the electro-osmotic flow, but also the charge
and molecular recognition properties of both the analyte and
the chiral selector. Clearly, all of these factors must be

TABLE XII

(A) 20 mM Rifamycin B
10%

20%

2-Propanol

2-Propanol

balanced in order to maximize resolution. AS has been

Compound

Rs time u(a)

u(e) Rs time u(a) u(e)

shown in Table X, the best resolution for racemic amino

Terbutaline
Norphenylephrine
Metoprolol

O.O 21.0
O.O. 18.9
O.O 20.7

3.4
5.1
3.3

alcohols is obtained at pH levels near 7, which produces
intermediate electrophoretic mobilities and migration times.

17.1
19.0
17.4

This example illustrates the effect of organic additives on
the Separation of enantiomers with rifamycin B using elec
trophoresis. All Separations were done using 20 mM rifa
mycin B in a solution of 70% 0.1M phosphate and 30% of
the organic additives as listed in Table XI below. The pH of
the Solution containing the rifamycin B was 7. The organic
additives are listed in Table XI below. All other aspects of
this example were conducted in accordance with Example

Compound
15

Compound

Rs time u(a)

u(e) Rs time u(a) u(e)

Terbutaline
Norphenylephrine
Metoprolol

0.3 18.6
O.O. 17.8
O.O. 18.8

5.0
5.9
4.8

0.4 30.0
O.O 27.3
OO 3O3

12.0
13.2
11.9

Rs time u(a)

u(e) Rs time u(a) u(e)

O.8 41.4
O.2 39.3
O.2 43.5

2.3
28
2.0

8.7
9.1
8.3

1.4 34.2
O.4 31.8
O2 33.9

10.5
11.3
10.6

2.2
2.7
2.O

2-Propanol + 0.5%
methyl t-butyl ether

2-Propanol

Compound

Rs time u(a)

u(e) Rs time u(a) u(e)

Terbutaline
Norphenylephrine

1.5 41.4
O.7 39.6

8.6
9.1

2.0
24

1.4 51.0
O.7 47.1

7.1
7.6

1.1
1.6

Metoprolol

0.3 40.2

8:5

1.9

O.3 49.8

7.2

1.O

1.5

41.7

8.6

2.O

O.7
O.3

39.6
42.2

9.1
8.5

2.4
1.9

40

below in Table XII.

u(e) Rs time u(a) u(e)

2.0 48.6

7.4

1.7

3.1

62.5

5.8

18

1.O 45.6
O.S. 49.2

7.9
7.3

2.2
1.6

1.5 54.6
0.8 62.1

6.6
5.8

2.7
1.9

EXAMPLE 16

This example illustrates the effect of sodium chloride on
the Separation of enantiomers with rifamycin B. All Sepa
rations were done using a 25 mM rifamycin B solution in
70% 0.1M phosphate and 30% 2-propanol solution at a pH
of 6. The apparatus and method of Example 11 above was
employed for obtaining the chromatographic data reported
TABLE XIII
OMNaCl

O.OSM NaCl

Compound

Rs time u(a)

u(e) Rs time u(a) u(e)

Terbutaline

18 42.6

8.4

2.5

1.4 52.2

6.9

2.O

O.9 41.1
O.4 48.6

8.7
7.4

2.7
1.5

O.8 45.9
O.3 55.2

7.8
65

2.9
1.6

50 Norphenylephrine
Metoprolol

O.1OMNaCl

Compound

Rs

time

At(a)

Al(e)

55

EXAMPLE 1.5

This example illustrates the effect of 2-propanol concen
trations on Separation of enantiomeric compounds using
electrophoresis as the Separation process. The apparatus and
method as described in Example 11 above was used in order
to obtain the chromatographic data in Table XII below. All
Separations were done using a 0.1M phosphate at a pH of 7
at the indicated Volume percent of 2-propanol. The amount
of rifamycin B used each of the Separations is also indicated

40%

2-Propanol

in Table XIII below.

AS can be seen in Table XI, the organic modifiers have a
profound effect on enantiomeric resolution, electrophoretic
mobilities and migration times. The addition of 2-propanol
relative to equivalent volume percents of other organic
additives. Although the 2-propanol also tends to produce
longer migration times and lower electrophoretic mobilities,
Some of the organic modifiers that produce comparable or
longer migration times did not produce equivalent enanti
oSelectivity Separations.

30%

2-Propanol

Rs time u(a)

35

45

to the Solution tends to enhance enantiomeric resolution

Al(e)

low 2-propanol concentration has no enantio-resolution of
any of the analyte tested. AS the concentration of organic
modifier increased, the electrophoretic mobilities decreased,
the migration times increased, the electro-osmotic flow
decreased, and the enantio-Separation is enhanced.

1-Propanol

Compound

At(a)

AS can be seen above, the data in Table XII shows that a

3.1
4.2
2.9

Terbutaline
Norphenylephrine
Metoprolol

time

Norphenylephrine
Metoprolol

Terbutaline
25 Norphenylephrine
Metoprolol

Methanol

Rs

Terbutaline

Compound
TABLE XI

Ethanol

2.8
3.7
24

(B) 25 mM Rifamycin B

11 above.

19.3
20.2
19.1

12.2
13.2
11.7

30% 2-Propanol

EXAMPLE 1.4

Acetonitrile

0.5 29.4
O.O 27.3
O.O 30.6

60

65

Terbutaline

1.1

54.3

6.6

1.6

Norphenylephrine
Metoprolol

O.7
O.2

46.2
57.6

7.8
6.2

2.8
1.3

AS can be seen, increasing the ionic strength uniformly
decreased enantiomeric resolution even though migration
time increased and electrophoretic mobilities decreased. AS
can be seen, increasing the ionic strength produced very
Similar effects to increasing the concentration of 2-propanol
with respect to migration times and electrophoretic mobili
ties. In both cases, migration times increased, while elec
trophoretic mobilities decreased.

5,874,005
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EXAMPLE 1.7

run Separated a mix of dansyl-D,L-methionine while the
Second run Separated a mix of dansyl-D,L-C.-amino-nbutyric acid. Separation of the enantiomers was obtained in
each case and the respective R values were 19.7 and 20.0.
In a third run a mix of dansyl-D,L-glutanic acid was
resolved using a buffer at a pH of 6.0 and a voltage of -5 kV.
Other runs were made with commercially available race
mic dansyl derivatized amino acids. Resolution of the enan
tiomers was achieved with resolutions as high as 15-20

This example illustrates the effect of buffer concentration
and buffer composition on the Separation of enantiomers
with rifamycin B in electrophoresis. Using the apparatus and
method of Example 11 above, all Separations were done with
20 mM rifamycin B and 70% 0.1 aqueous buffer as indicated
in Table XIV below and 30%. 2-propanol. As shown in Table
XIV below, the optimum concentration of phosphate buffer
appears to be 0.1M.

obtained.
TABLE XIV
O.OSM

O.1OM

Phosphate

Phosphate

In yet another run a mix of N-2,4-dinitrophenyl-D,Lglutanic acid was resolved using a buffer at a pH of 6.0 and
a voltage of -5 kV. Other N-2,4-dinitrophenyl amino acid

Compound

Rs time u(a)

u(e) Rs time u(a) u(e)

Terbutaline
Norphenylephrine
Metoprolol

1.O 38.1
O.6 34.8
O.2 37.8

2.2
3.0
18

9.4
100
9.5

1.5 41.7
O.7 39.6
O.3 42.2

8.6
9.1
8.5

15

included those of ethionine, citrulline, Serine, methionine,

2.O
2.4
1.9

0.05M Boric Acid +

0.15M Phosphate

0.05M Phosphate

Compound

Rs time u(a)

u(e) Rs time u(a) u(e)

Terbutaline

1.O 45.0

8.0

2.O.

11

42.6

8.4

1.9

Norphenylephrine
Metoprolol

O.S. 42.3
O.2 45.3

8.5
7.9

2.5
1.8

O.2 35.0
O.1 37.5

10.3
9.6

3.0
1.9

25

EXAMPLE 1.8

This example illustrates the use of Vancomycin to Separate
a variety of chiral compounds using capillary electrophore
Sis.

The apparatus and method of Example 11 above was used
with a fused Silica capillary measuring 25 cm to detector

(32.5 cm total) in length and having an inside diameter of 50

derivatives were also resolved. These other derivatives

35

norleucine, norvaline, C.-amino-n-butyric acid and C.-amino
n-caprylic acid.
Other runs were made using Vancomycin to Separate
various chiral compounds using the electrophoresis proceSS
and apparatus of this example. The N-3,5-dinitrophenyl
derivatives of ethionine, leucine, Serine, phenylalanine,
tryptophan, methionine, nor leucine, norvaline, and
C.-amino-n-butyric acid were resolved. Respective D.L
mixes of the alanine, Valine, leucine, phenylalanine,
methionine and phenylglycine derivatized with N-benzoyl
groupS and 3,5-dinitrobenzoyl groups were resolved. Vari
ous D.L mixes of N-carbobenzyloxy amino acids were
resolved. Various D.L mixes of N-phthalyl and N-phthalyl
glycoyl amino acids were resolved. Enantiomers of
ibuprofen, indoprofen, flurbiprofen, carprofen, Suprofen,
fenoprofen and p-hydroxymandelic acid were resolved.
Additionally, warfarin and coumachlor, which are neutral
compounds, were also resolved.

micrometers. Separations were obtained by using 5 mM
vancomycin in a 0.1M phosphate buffer.

EXAMPLE 1.9

In one Series of runs, amino acid derivatives of

N-hydroxy-Succinimidyl-6-amino quinoline carbamate

40

(AQC) were separated. In each run the voltage was +5 kV
and the pH of the buffer was 7.0. One run entailed separating
a D.L mix of an O-amino-n-butyric acid derivatized with
AQC and the other run entailed Separating a D.L mix of a
phenylalainine derivatized with AQC. Separation of the
enantiomers was obtained in each case and the respective R.

45

graphic (TLC) resolution of 6-aminoquinolyl-NhydroxySuccinimidyl carbamate (AOC) derivatized amino

acids, racemic drugs and dansyl amino acids. Excellent
Separations were achieved for most of these compounds in
the reversed phase mode. Both the nature of the stationary
phase and the composition of the mobile phase Strongly

values were 9.71 and 8.07.

Other runs were made with AOC derivatives of the

protein amino acids and those of many other amino acids. In
each case Vancomycin was able to resolve the enantiomers.
The average resolutions of 5-10 were achieved.
In another Series of runs, enantiomers of dansyl amino
acid derivatives were separated. In the first two runs the
voltage was +5 kV and the buffer had a pH of 4.9. The first

This example illustrates the use of a macrocyclic antibi
otic of the present invention for Separation of chiral mol
ecules using a thin-layer chromatographic technique.
The macrocyclic antibiotic, Vancomycin, was used as a
chiral mobile phase additive for the thin-layer chromato

50

influenced enantiomeric resolution. The best results were

obtained using diphenyl Stationary phases. Acetonitrile was
the organic modifier that produced the most effective Sepa
rations with the shortest development times. The results
from the various runs are reported in Table XV below.
TABLE XV

Compound

RF1

Rf

C.

Ra

Conc. (M)

Mobile Phase

1.

O.14
O.58
O.04
O.O2

O.2O
O.63
O.O6
O.O6

1.4
1.1
1.5
3.0

2.5
1.6
1.2
18

O.OS
O.OS
O.O4
O.OS

4f670
4f670
2/10/O
O.5/8.5/1

0.13(L)

0.16(D)

1.2

1.9

0.025

2/10/O

Coumachlor

2. Indoprofen
3.
4.

5.

Warfarin
Bendroflume
thiazide

AQC-C-amino

phenylacetic acid

5,874,005
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TABLE XV-continued
Compound

Rf

RF2

C.

Ra

Conc. (M)

Mobile Phase

6.

O.12
O.11

O.18
O.19

1.5
1.7

2.5
2.2

O.04
O.O25

0.01 (L)
0.06(L)

0.03(D)
0.10(D)

3.O
1.7

13
1.5

O.04
O.04

2/10/O
2/10/O
2/10/O
2/10/O

AQC-3-amino-3phenylpropinic acid

7. Dansyl-tryptophan
8. Dansyl-valine

9. AQC-leu-leu
(0.04M, 2/10/0)

(0.02M, 1.5/4.5/O),

R (D-L) R(L-D)

C. (DLLD) Rs (DLLD)

O.O3

O.10

3.3

R(L-L)

R(D-D)

C-(LDLD) Rs (LDLD)

O.04

O.24

R(D-L) R(L-D)

6.O

5.0
11.6

C. (DLLD) Rs (DLLD)

0.17

O.22

1.3

R(L-L)

R(D-D)

C-(LDLD) Rs (LDLD)

4.5

O.18

O.42

2.3

18.5

mobile phase compositions listed indicate the volume ratios of acetonitrile/0.6M NaCl/1% triethylam
monium acetate buffer (pH = 4.1).
AQC stands for 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, a fluorescent-tagging agent (see
Experimental section).

All racemic analytes, the Vancomycin, all dansyl amino
acids and the AOC derivatizing kit which was used to make

the various derivatives of AOC were obtained from com

mercial sources. The TLC plates were chemically bonded

diphenyl-F reversed phase plates (5x20 cm, 250u layer
thickness) and were also obtained from a commercial

25

Using a coating Solvent of ethyl ether and dichlo
romethane and conventional capillary gas-liquid chromatog
raphy apparatus, the Vancomycin was derivatized with an
n-butyl or n-hexyl isocyanate. This was done in a conven
tional manner. The optical isomers for which partial Sepa
ration were obtained are listed in Table XVI below.

SOCC.

The Vancomycin was first dissolved in the 0.6m sodium
chloride Solution and placed in an ultraSonic bath for about

TABLE XVI

15 minutes. Then the organic modifier (acetonitrile) was
were developed at room temperature (22 C.) in 6 (i.d.)x23

Compound

added to complete the mobile phase mixture. The plates

cm cylindrical glass chambers. It took approximately 1-3
hours to completely develop a 5x20 cm TLC plate. All
compounds were fluorescent. Spot visualization was done
by using a fixed-dual wavelength (254 nm and 365 nm)
ultraViolet hand lamp.

Vancomycin

35

The AOC derivatives were obtained in a conventional

3-chloro-2-norborn anone

35 + 2/min.

2-ethoxy-tetrahydrofuran
methyl-2-chloro-propionate

30 + 1/min.
35 + 1/min.

B-butyro-lactone

3O

1.2-epoxyhexane

30 + 1/min.

1-Pentene-3-ol
B-citronellene

30 2/min.
3O
Bebeerine

manner, as disclosed in Pawlowska et al., J.

Chromatography, Vol. 641, p. 257 (1993). Approximately
100 pmol of each isomeric compound was dissolved in 60

40

uL of sodium borate buffer (0.2M, pH 8.8) in a vial and

vortexed for several seconds; then 20 till of AQC solution

was added (3 mg per 1 IL of acetonitrile). The vial was
heated in an oven for 10 minutes at 50° C. The resulting

solutions were used in TLC without further purification.
The diphenyl-type Stationary phase gave the best results
in terms of low Streaking and good Spot integrity during
development. The racemates resolved were of three types:
underivatized pharmaceuticals, AQC-amino acids and dan
Sylamino acids. When enantiomerically pure Standards were

+ 2/min.

proceSS.
55

60

EXAMPLE 2.0

This example illustrates the partial Separation of optical
isomers using bebeerine and a derivative of Vancomycin by
gas-liquid chromatography.

+ 2/min.

This example illustrates using a macrocyclic antibiotic of
the present invention as a separation agent in a precipitation

of all AQC-amino acids and dansylamino acids (for which
standards were available) were the same. The D-enantiomer
It should also be noted that besides providing good
Separation and enantioselectivity, the Vancomycin also
maintained a relatively Small spot Size during development.

+ 2/min.
+ 2/min.
+ 2/min.

EXAMPLE 21

50

baseline resolved. It should be noted that the retention order

always had a greater R value than the L-enantiomer.

35
40
35
35
35
45

Separation was accomplished in a conventional manner
using conventional capillary gas-liquid chromatography.
The Separation, however, was only partial.

available, the retention order was determined as shown in

on the TLC plate. Most of the racemates were better than

C-pinene
C.-methyl-benzyl-amine
B-butyro-lactone
2-acetyl-5-norborene
3-chloro-butanone
3-methyl-cyclohexanol

45

Table XV above. The mobile phase generally consisted of
between 17 and 40 volume percent acetonitrile plus 0.6M

NaCl. The salt in the water helped to stabilize the binder

Oven Temp. (C.)

65

Into a beaker containing 25 ml water and 25 ml of
acetonitrile and 0.25 grams of indoprofen, the macrocyclic
antibiotic Vancomycin is added. Such a Solution is Super
Saturated with the macrocyclic antibiotic by adding Small
portions of the organic Solvent component.
The macrocyclic antibiotic complexes with indoprofen
and causes a precipitate to form. The precipitate is recov
ered. Next, the recovered precipitate is added to water and
heated to cause the complex between the macrocyclic anti
biotic and indoprofen to break. The enantiomerically
enriched compound is then recovered Separately from the
macrocyclic antibiotic. The macrocyclic antibiotic is then
recovered and used again.

5,874,005
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EXAMPLE 22

EXAMPLE 23

This example illustrates using a macrocyclic antibiotic,
Vancomycin, affixed to Silica gel to obtain resolution of
Several racemic pyridones.
Using a conventional HPLC technique and a mobile phase
of a 10/90 mix of acetonitrile and 1% triethylammonium
acetate buffer at a pH of 7, the analogues which were
Separated into Substantially pure form are reported in Table

This example illustrates the use of rifamycin B in affinity
chromatography to Separate DNA polymerase from Solution.
Rifamycin B is affixed to a Silica gel in accordance with
the present invention. A conventional liquid chromato
graphic column is packed with the Solid Support of rifamycin
B bonded to the silica gel. Next, a sample containing DNA
polymerase is injected into the column. The column is

XVII below.

TABLE XVII
O

R1

operated in a conventional manner using conventional
15 equipment in order to obtain Separation of the DNA poly

N -H

CSC.

R2

21 NoMe
CN

2O
R1

R2

H

Me

Lic

R

R

'p

Ph

H

LAPh

H
H

CH11
CHPh

LCH
LBz

H

MeO2C

This example illustrates using ristocetin A as a chiral
Selector in capillary electrophoresis.
25

L

Enantiomeric resolutions, migration times, and apparent

M1

and effective mobilities of enantiomers of amino acid

H

LM2

30 acids separated with ristocetin. The pH and concentration of
ristocetin are indicated. The results are reported in Table
XVIII, below.

H

LMe

-CH

derivatives, nonsteroidal anti-inflammatory, and carboxylic

Me

ch,
MeO2C

EXAMPLE 24

Code

CH2

35
CH

Note this is a powerful Separation technique for anions,
neutral molecules. It appears to be able to resolve most

N-derivatized amino acids as well. A few representative
examples are shown below.
TABLE XVIII

Compound

Resolution time(1) time(2)

u(1) u.(2)

AQC Amino Acids'
Alanine

pH 7.0 9.4

8.8(D) 12.6(L)

-2.5 -8.0

Valine

bH 7.O

10.5

2.6

-5.4

Leucine
FMOC Amino Acids

pH 7.0 5.4

9.5(D)

1.3(L)

-3.9 -6.5

Valine
Alanine

bH 7.0
bH 7.O

12.1
14.7

6.6
5.0

-3.6
-6.0

6.O.

9.0
O.4

-8.0

-7.3
-6.2

DOPS (3,4-Dihydroxyphenylserine)

bH 7.O

13.8

11.4

8.6

-2.8

-8.4

Cirtrulline
Norleucine
Serine

bH 7.O
bH 7.O
bH 7.O

2.6
O.7
2.4

9.1
7.4
10.9

O.O
7.6
2.1

-1.3
-3.1
-4.2

-2.8
-3.7
-5.6

Valine
Leucine

bH 6.O
bH 6.O

20
3.9

138
11.3

4.6
5.6

-5.8
-3.3

-6.5
-7.2

Aspartic acid

pH 6.0 5.6

37.2(D) 46.5(L)

Methionine
Noreleucine"

bH 7.O
bH 7.O

7.1
15.2

8.2
22.6

1.O
33.1

-1.0
-2.1

-6.2
-4.3

bH 6.O.
bH 6.0

O.4
9.0

18.4
9.2

20.2
13.4

-5.3
-3.2

-6.1
-8.8

Dansyl Amino Acids'

2,4-Dinitrophenyl Amino Acids'

-13.3 -14.1

N-3,5-Dinitropyridyl Amino Acids'
Alanine
Leucine

5,874,005
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TABLE XVIII-continued

Compound
Carbobenzyloxy Amino Acids'

Resolution time(1) time(2)

At (1) it (2)
5.7
-3.0

-7.3
-6.9

3.0

-6.1
-3.8

-6.4
-5.1

2.1
O

8.1
3.6

-1.3
-6.3

-5.8
-9.0

5.2
O.7

8.1
4.0

O.9
4.6

-4.9
3.9

-6.2
-4.3

bH 7.O
bH 6.O.

6.7
O.6

8.2
4.2

3.5
5.0

-1.0
-4.0

-9.0
-4.6

bH
bH
bH
bH
bH

6.O
6.O
6.O
6.O
6.O

1.7
13
1.2
5.7
14

27.2
2.7
2.1
2.3
7.0

28.
3.
2.3
4.3
7.4

-8.8
-4.8
-7.4
-4.4
-8.1

-9.0
-5.2
-7.8
-6.2
-6.7

2-Phenoxypropionic acid
2-(2-Chlorophenoxy)propionic acid
Proglumide'
+-Dibromohydrocinnamic acid
Indolelactic acid
+-trans-4-Cotinine carboxylic acid
Iopanoic acid
Iophenoxic acid
2-(4-Hydroxyphenoxy)propionic acid
B-Phenylactic acid
Tropic acid
3-4-Carbonyl-PROXYL
Folinic Acid

bH
bH
bH
bH
bH
bH
3H
bH
bH
bH
bH
bH
bH

6.O.
6.O
6.O
6.O
6.O
6.O
6.O.
6.O.
7.O
6.O
6.O.
6.0
6.O

O.8
21
1.5
S.O
3.4
16
12.3
12.5
1.O
O.7
O.2
9.1
13

21.O
9.5
4.1
20.5
2.5
20.1
8.6
10.9
27.O
6.2
21.4
26.1
14.8

21.7
21.4
14.5
23.4
17.
21.6
11.
13.4
29.
16.8
21.8
34.3

-13.5
-13.4
-9.8
-7.6
-11.5
-7.3

Atrolactic acid

bH 6.O.

O.4

28.6

29.1

-13.2
-12.6
-9.4
-6.9
-8.0
-6.7
-2.3
-6.2
-9.1
-4.7
-13.4
-12.9
-10.0
-15.3

Glutamic acid

bH 6.O

2.7

Methionine

bH 6.O

8.6

3.6

5.7

Cl-Amino-n-butyric acid

bH 6.O.

O.1

4.1

4.5

Methionine

bH 6.O

2.7

7

bH 6.O
bH 6.O

6.8
3.7

bH 6.O
bH 6.O

.1(D) 15.2(L)

PHTH-Amino Acids

N-Benzoyl Amino Acids'
Methionine
Leucine

N-Formyl Amino Acids'
Tryptophan
Phenylalanine

N-Acetyl Amino Acids'
4-Fluorophenylalanine
Phenylalanine

Non-Steroidal Anti-inflammatory Drugs'
Flurbiprofen
Indoprofen
Carprofen
Ketoprofen
Suprofen

Other Carboxylic Acid Compounds

16.8

-6.5
-9.1
-9.2
-5.1
-13.5
-14.4
-11.3
-15.4

"Migration time (in minutes) of the first eluting enantiomer.

Migration time (in minutes) of the second eluting enantiomer.

u(1) and u(2) are the effective electrophoretic mobilities of the first and second eluting

enantiomer in cm kV' min".
2 mMristocetin added to run buffer.
5 mM ristocetin added to run buffer.

2 mMristocetin added to run buffer with 10% 2-propanol.
"2 mMristocetin added to run buffer with 30% 2-propanol.
This is a diastereomeric separation of folinic acid.

82 mM ristocetin added to run buffer with 20% 2-propanol.

These tests were run with a Quanta 4000 (Waters) capil
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lary electrophoresis apparatus equipped with a fixed wave
length UV lamp. All chiral Separations were performed

temperature (22 C.). All materials used for this test were

using a 50 um (i.d.)x32.5 cm (25 cm to detector) fused silica

capillary obtained from QuadreX Corporation and detected
at 254 nm. The capillary was prepared daily by conditioning
with 0.1M potassium hydroxide for 10 minutes. Next, the
capillary was purged with distilled water for 5 minutes
followed by the appropriate concentration and pH of the run
buffer for an additional 5 minutes. The 0.1M sodium phos
phate buffer Solutions were prepared in a Volumetric flash
and adjusted to the desired pH with sodium hydroxide. The
ristocetin Solution was prepared in a Volumetric flask, dis
Solved in the appropriate phosphate buffer, and degassed by
Sonication. The aqueous buffer/organic modifier

conventional.
55
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(2-propanol) mixture was prepared by volume. All Samples

were dissolved in distilled water and filtered with a 0.45 um
nylon Syringe filter from Alltech prior to injection. The run
Voltage for all Separations was +5 kV. Samples were hydro

Statically injected for 3 or 5 Seconds. Chiral Separations were
achieved with solutions of 0.1 mg/mL and at ambient

65

Over 120 racemic compounds have been Separated and
Table XVIII lists a representative selection of those com
pounds that were resolved using dilute Solutions of ristocetin
A. This includes all types of N-blocked amino acids and a
variety of other acidic or anionic compounds. Nonsteroidal
anti-inflammatory compounds are particularly easy to
resolve. The enantioselectivity of ristocetin A appears to be
Somewhat Similar to that of Vancomycin. However, Several
chiral compounds containing carboxylic acid functional
groups were resolved with ristocetin A that could not be
Separated with Vancomycin. These include: mandelic acid,
2-methoxy mandelic acid, O-acetylmandelic acid,
3-methoxymandelic acid, B-phenylactic acid, tropic acid,
2-bromo-3-methylbutyric acid, 1-benzo cyclobu tene
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carboxylic acid and p-chloromandelic acid among others.
Ristocetin A appears to be complimentary to rifamycin B

aforementioned factors. A similar “wall-interaction effect”

was previously noted for Vancomycin. The wall adsorption
does not seem to affect the run to run reproducibility as long
as all experimental conditions are held constant.

and heparin (which resolve cationic compounds) when used
as a CE chiral Selector.

There are at least four other distinguishing features of
ristocetin A-based CE Separations compared to previous
Vancomycin-based Separations. First, at all concentrations

The effective mobilities (u, e) of the analytes (which have

electromigrations opposite to the direction of the electroOS

motic flow) decrease with increasing concentration of ris

tocetin A. This is because a greater amount of the analyte is

between 2 and 5 mM ristocetin A (without added organic
co-Solvent modifiers) the Separation times were significantly

less than those obtained using Vancomycin. Separation times
with Vancomycin as a chiral Selector and using analogous
conditions were typically between 40 and 70 minutes.
Second, as will be shown, organic modifiers can be used to
Substantially enhance enantioresolutions when using risto
cetin A, but leSS So with Vancomycin. Third, aqueous Solu
tions of ristocetin A appear to decompose more slowly than
those of Vancomycin. Finally, the current cost of Vancomy

asSociated with the ristocetin A when the concentration of

the chiral Selector is increased. Hence the improvement in
the enantiomeric Separations at higher ristocetin A concen

trations seems to be the result of two factors: (1) a greater
time of association between the chiral Selector and analytes
15

due to mass action and (2) a greater time of association

between the chiral Selector and analyte due to the decrease
in the electroosmotic flow.
EXAMPLE 26

cin is much less than that of ristocetin A.

This example illustrates the effect of pH on the migration

EXAMPLE 25

This example illustrates the effect of ristocetin concen
tration on the migration times, effective mobilities, and the
resolution of enantiomers. The run buffer was 0.1M phos
phate buffer, pH 6, containing the indicated concentration of
ristocetin. The results are reported in Table XIX, below.
These tests were run as in Example 24, above.

times, effective mobilities, and resolution of enantiomers

with ristocetin as a chiral Selector. All Separations were
performed using 2 mMristocetin in 0.1M phosphate buffer.
Table XX, below lists the results obtained.
25

TABLE XX

Compound

TABLE XIX

Compound

Rs

t(1)

to)

teof)

At (1)

(2)

2-(3-

8.9

11.2

21.4

7.6

5.7
1.5

12.3
16.8.

14.3
20.2

7.5
7.6

Ketoprofen
3-Methoxymandelic
35 acid
1-Benzocyclobutene-4.4 -6.2
-11.5 -13.0
carboxylic acid

1.1

21.0

22.4

7.5

-13.2 -13.7

chlorophenoxy)propionic acid
Ketoprofen
3-Methoxymandelic
acid
1-Benzocyclobutene-

-3.1 -10.0

carboxylic acid

2-(340

22.1

116

29.3

11.5

-0.2

-8.7

teof)

At (1) it (2)

8.9

11.2

21.4

7.6

-3.1 -10.0

5.7
1.5

12.3
16.8.

14.3
20.2

7.5
7.6

-4.4 -6.2
-11.5 -13.0

1.1

21.0

22.4

7.5

-13.2 -13.7

5.1

10.1.

13.8

7.5

-4.9

-9.2

2.6
1.1

12.6
18.1

13.7
20.2

7.5
7.4

-8.1
-5.8

-9.1
-6.7

7.4
4.7

15.7
19.2

27.5
29.9

11.5
11.5

-3.8
-5.8

-5.5
-8.8

0.4

21.6

220

7.5

1.8

42.5

49.6

11.5

chlorophenoxy)propionic acid
Ketoprofen
3-Methoxymandelic
acid
1-Benzocyclobutene-

chlorophenoxy)propionic acid
Ketoprofen
3-Methoxymandelic
acid
1-Benzocyclobutene-

to)

pH 7

5 mM Riatocetin

2-(3-

t(1)

chlorophenoxy)propionic acid

2 mM Riatocetin

2-(3-

Rs

pH 6

-13.4 -13.6

carboxylic acid
45

-10.3 -10.9

"The migration times of the enantiomers, tC1) and t(2), are given in minutes.

carboxylic acid

The time corresponding to the electroosmotic flow, tCeof), is given in

"The migration times of the enantiomers, tC1) and t(2), are given in minutes

minutes. Note that a decrease in the eof velocity results in an increase in
t(eof).

The time corresponding to the electroosmotic flow, tCeof), is given in
The effective mobilities, ue(1) and ue (2) are given in cm’ kV 1 min".

minutes. Note that a decrease in the eof velocity results in an increase in teof)

The effective mobilities, u(1) and u (2) are given in cm kV - 1 min".

50

As shown in Table XIX the concentration of ristocetin A

in the run buffer can have a significant effect on the CE
Separation. In general, higher concentrations of the chiral
Selector produce higher enantioresolutions and longer Sepa
ration times. The reason for the increase in analyte elution
time is that higher concentrations of ristocetin tend to slow
the electroosmotic flow. This is because at these pHs the
positively charged ristocetin tends to interact with the wall
of the capillary. Increasing the phosphate buffer concentra

55

electroosmotic flow (thereby increasing analysis times) and
60

tions lessens the wall interactions Somewhat. However, there

is a “trade-off Since increasing buffer concentration also
increases heat generation, baseline noise and usually
requires a decrease in the run Voltage. The buffer concen

tration used throughout this project (i.e., 0.1M phosphate)

was a compromise after taking into account all of the

These results were obtained following the procedure in
Example 26, above.
Table XX shows the effect of pH on the enantioseparation
of typical racemic analytes. In general, Somewhat lower pHS
give better enantioresolutions. However, there is a limit to
this effect Since decreasing the pH will significantly decrease
eventually protonate the analytes making them neutral Spe
cies. At sufficiently low pHs, these two effects inhibit or
negate the CE enantioSeparation.
EXAMPLE 27

65

This example illustrates the effect of concentration of
2-propanol as an organic additive on the migration times,
effective mobilities and resolution of enantiomers with ris
tocetin as chiral selector. Table XXI lists the results below.
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TABLE XXI

Organic Solvent
None

Compound

R,

t(1)

t(2) tEOF) u(1) u(2)

2-(3-Chlorophenoxy)-

5.1

10.1.

13.8

7.5

1.9

9.2

propionic acid
Ketoprofen

2.6

12.6

13.7

7.5

3-Methoxymandelic acid

1.1

18.1 20.2

7.4

1-Benzocyclobutene-

O.4

21.6

220

7.5

5.8

14.6

21.3

5

-3.0

-6.5
-6.7
-9.2
-0.1
-6.2

-8.1 -9.1
-5.8 -6.7
-13.4 -13.6

carboxylic acid
10% 2-Propanol

2-(3-Chlorophenoxy)-

propionic acid
Ketoprofen

4.5

19.6

21.8

5

3-Methoxymandelic acid

1.8

28.0 33.2

5

1-Benzocyclobutene

O.7

40.2

40.O

5

-5.8
8.3
-10.1

7.6

21.4

30.8

8

-2.7

carboxylic acid
20% 2-Propanol

2-(3-Chlorophenoxy)-

propionic acid
Ketoprofen

5.7

26.3

29.8

8

3-Methoxymandelic acid

2.3

39.6 47.5

8

1-Benzocyclobutene-

11

55.0

57.9

7

1O.O

26.6

47.7

4.5

7.6 -8.4
-9.7 -10.4
-10.9 -11.0

carboxylic acid
30% 2-Propanol

2-(3-Chlorophenoxy)-

-2.4

-5.1

propionic acid
Ketoprofen

5.79 37.6

43.1

4.6

3-Methoxymandelic acid

5.22 63.5 89.6

4.5

1-Benzocyclobutene-

1.23 70.1

73.7

-4.2 -4.8
-6.0 -6.7
-11.3 -11.6

.6

carboxylic acid

All separations were performed using 2 mM ristocetin in 0.1M phosphate buffer (pH 7) with
the indicated volume percentage of organic solvent.
"The migration times of the enantiomers, tC1) and t(2) are given in minutes.

The time corresponding to the electroosmotic flow tEOF), is given in minutes. Note that a
The effective mobilities, u(1) and u(2), are given in cm kV 'min'.

decrease in the EOF velocity results in an increase in tCEOF).

These results were obtained following the procedure
outlined in Example 24 above.
AS found in the case of another macrocyclic antibiotic

(rifamycin B) the use of organic modifiers can significantly

TABLE XXII

alter enantioresolutions in Some cases. The addition of

2-propanol to the run buffer tended to enhance enantioreso
lutions for most analytes. Also the organic modifier greatly

increased analyses (elution) times as a result of the decreas
ing electrooSmotic flow velocity. The effect of enhancing
enantioresolutions with added organic modifier varies with
the analyte. Eventually a level of organic modifier is reached
that decreases enantioresolutions. Also when using hydro
organic Solvent mixtures in CE for longer periods of time,
one must take precautions to prevent differential evaporation
of the solution which will affect reproducibility, analysis

t1.

t2

bromacil

9.6

10.6

Van(1)

8.0
7.9
12.6

9.5
8.6
16.3

TeiO2)
Van(3)
Tei)

4-phenyl-5-cyano-6-

methoxy-3,4-dihydro-2-

pyridone()
40

Column

devrinol

10.3

12.1

Van(1)

11.6

12.9

Tei (2)

warfarin

9.6

11.6

Van(1)

3-methyl-5-cyano-

5.4

5.8

Van(3)

9.4
9.7

11.0
12.O

Van(3)
TelC4)

11.4
8.6

12.O
11.6

Van(3)
Teio)

15.2
14.9

16.2
20.3

Van(3)
TelC4)

6-methoxy-3,4-dihydro-2pyridone
45

4-methyl-5-cyano6-methoxy-3,4-dihydro-

2-pyridone
3,4-diphenyl-5-cyano6-methoxy-3,4-dihydro-

times, resolution, etc.

Ristocetin A can decompose with time in aqueous Solu
tion. This process is accelerated at acidic or basic pHS and
at elevated temperatures. For example, acid hydrolysis
removes the Sugars and an amine containing fragment from
the molecule. Interestingly the degradation product remains
active against Gram-positive bacteria. However, the overall
Stability of ristocetin A under typical CE operating condi

Compound
35

2-pyridone
50

4-cyclohexyl-5cyano-6-methoxy-3,

4-dihydro-2-pyridone

The column was a 25 cm x 0.44 cm (i.d.) bonded vancomycin CSP (5 um

55

tions (e.g., pHs 5-7 and temperatures 15-25 C.) seems to
exceed that of Vancomycin. We have used solutions of
ristocetin A up to 4 weeks provided they are refrigerated

(~4 C.) overnight or when otherwise not in use.
60

EXAMPLE 28

This example illustrates that closely related macrocyclic

silica gel). The mobile phase consisted of 10:90 acetonitrile-1% pH 4.1
triethylammonium acetate buffer (by volume), 1.0 ml/min.
(*)The column was a 25 cm x 0.44 cm (i.d.) bonded teicoplanin CSP (5 um
silica gel). The mobile phase was the same as that in (1), above.
The column was a 25 cm x 0.44 cm (i.d.) bonded vancomycin CSP (5 um
silica gel). The mobile phase consisted of 10:90 methanol-1% pH 4.1
triethylammonium acetate buffer (by volume), 1.0 ml/min.
('The column was a 25 cm x 0.44 cm (i.d.) bonded teicoplanin CSP (5 um
silica gel). The mobile phase was the same as that in (3).
The column was a 25 cm x 0.44 cm (i.d.) bonded vancomycin CSP (5 um
silica gel). The mobile phase consisted of 30:70 methanol-1% pH 4.1
triethylammonium acetate buffer (by volume), 1.0 ml/min.
The column was a 25 cm x 0.44 cm (i.d.) bonded teicoplanin CSP (5 um
silica gel). The mobile phase was the same as that in (5).

antibiotics when used as chiral Selectors have Somewhat

Similar but not identical Selectivity. In this example Vanco
mycin is compared to teicoplanin as a chiral Stationary
phase. The results are listed in Table XXII, below.

65

One of the things which has been found with respect to the
teicoplanin columns is that it does a good job at resolving
native, underivatized amino acids and Some dipeptides.
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(7) Mobile Phase: 25:75 volume ratio of ethyl alcohol to

These tests were made using conventional liquid chroma

tography (HPLC) using identical columns except for the

hexane

bonded macrocyclic antibiotic.

Flow Rate: 1 ml/min.

Injection Volume: 30 microliters
Sample Concentration: 0.1 mg/ml

EXAMPLE 29

This example illustrates good results obtained using a
vancomycin as a chiral stationary phase. Table XXIII lists

(8) Mobile Phase: 100% ethyl alcohol ammonium nitrate,
pH 5.5

the results.

Flow Rate: 1.5 ml/min.

Injection Volume: 5 microliters
Sample Concentration: 4 mg/ml
Column operated in normal phase

TABLE XXIII
to

K'

K'

C.

Rs

Bendroflumethiazide (1)

Compound

2.8

S.O

5.8

16

183

4-Benzl-24-Benzl-2-

2.8

2.46

3.09

26

1.75

Bromacil (1)
Coumafuryl (3)
Devrinol (4)
Fenoterol (5)
Ketamine (1)
Luciferin (6)
Mephobarbitol (7)

2.8
2.8
2.8
2.8
2.8
2.8
2.8

2.44
3.13
2.7
1.45
2.97
1.73
1.56

2.78
437
3.3
1.93
3.57
2.28
1.95

.14
.4
.24
33
2O
32
25

1.51
2.96
2.42
2.06
2.30
1.96
2.15

5-Methyl-5-

1.85

O.78

1.32

69

2.18

Flow Rate: 0.5 ml/min.

2.8

1.57

2.13

36

3.0

Phensuximide (10)
Proglumide (11)
Pyridoglutethimide (12)

2.8
2.8
2.8

4.5
2.31
2.8,

4.9
3.30
3.3

O9
43
.2

1.67
3.7
18

Injection Volume: 10 microliters
Sample Concentration: 4 mg/ml

3a,4,5,6-Tetrahydro-

2.8

2.8

3.33

.2

1.62

Flow Rate: 1 ml/min.

2.57

Injection Volume: 3 microliters
Sample Concentration: 2 mg/ml

(9) Mobile Phase: 90:10 volume ratio of tetrahydrofuran to
15

Oxazolidinone (2)

Phenylhydanatoin (9)

(10) Mobile Phase: 70:30 volume ratio of hexane to ethyl
alcohol

25

(11) Mobile Phase: 10:90 volume ratio of tetrahydrofuran to
20 mM ammonium nitrate, pH 5.5

succinimido-3,4-b
acenaphthen-10-one (13)
Warfarin (14)

2.8

2.42

3.14

3O

C-Methyl-benzylamine (15)

2.8

3.6

4.2

15

1.47

Flurbiprofen (16)

2.8

2.47

3.23

22

1.95

Column Operating Parameters

(1) Mobile Phase: 10:90 volume ration of tertrahydrofuran

(12) Mobile Phase: 10:90 volume ratio of acetonitrite to
0.1% of triethylammonium acetone buffer, pH 5.5
Flow Rate: 1.1 ml/min.
35

to 20 mM ammonium nitrate, pH 5.5

hexane

Flow Rate: 1 ml/min.
40

(2) Mobile Phase: 70:30 volume ration of hexane and ethyl
alcohol

0.1% triethylammonium acetone buffer, pH 5

45

20 mM ammonium nitrate, pH 5.5

(15) Mobile Phase: 90:10 hexane to ethyl alcohol

Flow Rate: 1.2 ml/min.

Flow Rate: 0.5 ml/min.
50

(4) Mobile Phase: 20:80 volume ration of tetrahydrofuran to

20 mM ammonium nitrate, pH 5.5

Flow Rate: 1 ml/min.
55

20 mM ammonium nitrate, pH 5.5
Flow Rate: 1.1 ml/min.
60

measuring 25 cm by 4.6 mm (4.4 cm inside diameter) in a
conventional manner. A conventional liquid chromatograph

20 mM ammonium nitrate, pH 5.5
Flow Rate: 1.1 ml/min.

phase of Vancomycin or teichomycin and Silica beads (5u)

was prepared and packed into a Stainless Steel column

(6) Mobile Phase: 10:90 volume ratio of tetrahydrofuran to
Injection Volume: 6 microliters
Sample Concentration: 0.5 mg/ml

Flow Rate: 1 ml/min.

Injection Volume: 2 microliters
Sample Concentration: 2 mg/ml
Column, Column Preparation and Measuring Instruments
In order to Separate the different enantiomers a Stationary

(5) Mobile Phase: 10:90 volume ratio of tetrahydrofuran to
Injection Volume: 15 microliters
Sample Concentration: 0.5 mg/ml

Injection Volume: 1 microliter
Sample Concentration: 2 mg/ml

(16) Mobile Phase: 20:80 volume ratio of tetrahydrofuran to

0.1% triethylammonium acetate buffer, pH 5.
Injection Volume: 3 microliters
Sample Concentration: 2 mg/ml

Flow Rate: 1 ml/min.

Injection Volume: 1 microliter
Sample Concentration: 4 mg/ml

(3) Mobile Phase: 10:90 volume ration of tetrahydrofurin to
Injection Volume: 1 microliter
Sample Concentration: 2 mg/ml

Injection Volume: 1 microliter
Sample Concentration: 4 mg/ml

(14) Mobile Phase: 20:80 volume ratio of tetrahydrofuran to

Flow Rate: 1 ml/min.

Injection Volume: 1 microliter
Sample Concentration 2 mg/ml

Injection Volume: 15 microliters
Sample Concentration: 0.5 mg/ml

(13) Mobile Phase: 25:75 volume ratio of ethyl alcohol to

Flow Rate: 1 ml/min.

Injection Volume: 1 microliter
Sample Concentration: 2 mg/ml

Flow Rate: 1 ml/min.

Injection Volume: 4 microliters
Sample Concentration: 3 mg/ml
Column operated in reverse phase

Phenylhydanatoin (8)
5-Methyl-5-

20 mM ammonium nitrate, pH 5.5

65

with a UV detector (254 nm) was used to measure the
Separation. The columns were run in a conventional manner
at room temperature (25 C.) and the chart speed was 0.5
cm/min.
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EXAMPLE 30

which do not constitute a departure from the Spirit and Scope
of the invention.
What is claimed is:

This example illustrates separation via absorption bubble

technology (e.g. flotation, foam flotation, froth flotation,
floc-flotation, floc-foam flotation) using macrocyclic antibi

1. A process for Sequentially Separating enantiomers from
a fluid Solution containing Said enantiomers comprising the
Steps of

otics in accordance with the present invention.
Using the apparatus shown in FIG. 7, sample chamber 10
is filled with a Sample and chiral Separator 12. In this
example, acetonitrile and Vancomycin at a concentration of
12 mg/ml is diluted down to about 1% with appropriate

(a) treating a fluid containing said enantiomers by means

buffer. Next, 1 mL of racemic Solution and 19 mL of the

dilute Vancomycin Solution are placed into Sample chamber
10. On top of sample chamber 10 is foam column 14, which
is packed with glass beads 16. Air 18 is blown through
piping 20, through frit 22 and into sample chamber 10. The
air bubbles passing through Sample 12 cause a foam to be
formed. The height of the foam is controlled by the amount
of air. The foam tends to break-up as it passes through glass
beads 16 and produces a thin film of liquid that flows down

15

of chromatography with a macrocyclic antibiotic to
cause Said enantiomers to Sequentially Separate one
from another, Said macrocyclic antibiotic being
Selected from the group consisting of macrollides, non
glycopeptide macrocyclic peptides, polyenes and
derivatives thereof, Said macrocyclic antibiotic inter
acting with Said enantiomers to cause Sequential Sepa
ration by means of more than one of the following
mechanisms: complexation, charge-charge interaction,
hydrogen bonding, inclusion in a hydrophobic pocket,
dipole Stacking, or Steric interaction, and

the column (i.e. counter current to the foam migration). After

(b) recovering the sequentially separated enantiomers as

a steady counter current reflux condition is established, a
foam fraction is collected in container 24 by increasing the

2. The process of claim 1 wherein Said macrocyclic
antibiotic is affixed to a Support and Said treating Step
comprises contacting Said fluid with Said macrocyclic anti
biotic attached to Said Support.
3. The process of claim 1 wherein Said macrocyclic
antibiotic is a mobile phase additive.
4. The process of claim 1 wherein the Step of treating is
conducted using a chromatographic Separation process in
which Said mixture of enantiomerS is eluted through a
column wherein Said macrocyclic antibiotic is affixed to a
Support material and acts as a Stationary phase in Said

flow rate of air 18. One of the enantiomers in the racemic
Solution is then collected in container 24.
The concentration of the chiral Selector and racemic

individual enantiomers.

25

mixture must be optimized in each case as does pH.
In this way macrocyclic antibiotics are used to Separate
enantiomers using absorption bubble technology.
EXAMPLE 31

This example illustrates using Teichomycin as a chiral
Stationary phase.
Following the procedure in Example 29, above, Teicho
mycin was used as a Stationary phase to Separate the
enantiomers identified below. The column was operated in
the same manner as in Example 29 except as noted below:
D.L-Penylalanine
Mobile Phase: 40:60 volume ratio of methyl alcohol and
Water

column.
35

derivatives thereof.
40

Flow Rate: 1 ml/min.

Injection Volume: 1 microliter
Sample Concentration: 2 mg/ml
d.1-DOPA

45

Mobile Phase: 40:60 volume ratio of methyl alcohol and
Water

Flow Rate: 1 ml/min.

Injection Volume: 1 microliter
Sample Concentration: 5 mg/ml
2,6-dimethyltyrosine
Mobile Phase: 20:80 volume ratio of ethyl alcohol to
Injection Volume: 5 microliters
Sample Concentration: 2 mg/ml
It will be understood that the claims are intended to cover

all changes and modifications of the preferred embodiments
of the invention herein chosen for the purpose of illustration

6. The process of claim 2 wherein Said macrocyclic
antibiotic is chemically bonded to Said Support.
7. The process of claim 2 wherein Said macrocyclic
antibiotic is coated on Said Support.
8. The process of claim 1 wherein said macrocyclic
peptides is selected from the group consisting of
SporideSmollides, capreomycin, cycloSporins, tyrocidine,
trioStins, gramicidins, tyrocidines, polymyxins, bacitracins,
octapeptins, actinomycins, etamycins, Vernamycins,
enniatins, Valinomycin, thiostrepton, and derivatives
thereof.

50

9. The process of claim 1 wherein said polyenes is
Selected from the group consisting of amphotericin,
candicidin, candidin, dermostatin, fungichromin, nyStatin
and derivatives thereof.

Water

Flow Rate: 1 ml/min.

5. The process of claim 1 wherein said macrollides is
Selected from the group consisting of chalcomycin,
methymycin, neomethymycin, erythromycin, megalomycin,
picro my cin, narbo my cin, ole and O my cin,
triacetyloleandomycin, carbomycin, Spiramycin, tylosin and

55

10. The process of claim 1 wherein said support is
Selected from the group consisting of Silica gel, alumina,
poly Styrenes, polyurethanes, polyvinyl alcohols,
polyamides, agarose, cellulose, dextran and linear and
branched amylose.
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Column 8

Line 49, change "Anhydrous' to -- anhydrous --.
Column 9

Table II, No. 14), after "4.1” insert -- Van --;
No. 20; change “10196" to -- 10/90 --.
Column 10

Line 20, add at the end of the formula: -- f(t1-to) --.
Column 11

Table III, last line, change "4.41' to -- 1.41 --.
Column 12

Line 25, change "3,4-” to -3,4-b-.
Column 13

Table VII, No. 9) after "109" insert -- 15/85 DMP-Van --; No. 10), change" 1.03' to -1.08 --; No. 11), change “1.03” to -- 1.08 --.
Column 17

Table XI, last line, change "8:5' to -- 8.5 --.
Column 18. Table XIII

Line 51, change “65" to -- 6.5 --.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION
PATENT NO.
DATED

: 5,874,005
: February 23, 1999

Page 2 of 2

INVENTOR(S) : Daniel Armstrong
It is certified that error appears in the above-identified patent and that said Letters Patent is
hereby corrected as shown below:
Column 20

Table XV, No. 5, change "AQC” to -- AQC-.
Column 25

Table XVII, on line of Glutamic acid, change "5.7" to ---5.7-; on line of Suprofen,
change "-6.7" to -- -8.7-; on line of +-Dibromohydrocinnamic acid, change "-7.6’ to
---7.8 --.

Column 27, Table XIX
Line 31, change "Riatocetin' to -- Ristocetin --;
Line 40, change "Riatocetin' to -- Ristocetin --.
Column 29 Table XXI

Line 2, change" 1.9' to -4.9 -:
Line 11, change "8.3' to -- -8.3 -;
Line 12, change "40.0” to -- 40.6 -;
Line 16, change “7.6’ to -- -7.6 --.
Column 31 Table XXIII

Line 14, delete "4-Benzyl-2-”

Signed and Sealed this
First Day of January, 2002

JAMESE, ROGAN

Attesting Officer

Director of the United States Patent and Trademark Office

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION
PATENT NO.
DATED

: 5,874,005
: February 23, 1999

Page 1 of 2

INVENTOR(S) : Daniel Armstrong
It is certified that error appears in the above-identified patent and that said Letters Patent is
hereby corrected as shown below:

Title page,
Change "Amstrong to -- Armstrong --,
Item 75, Inventor, change “Amstrong” to -- Armstrong --.
Column 1

Line 67, change “Electrophbresis” to -- Electrophoresis --.
Column 5

Line 11, change "macrodites' to -- macrollides --.
Column 7

Line 7, after “to' (first instance), insert -- leash --.
Lines 29-30, change “trimethlyloxysilane' to -- trimethyloxysilane --.
Column 8

Line 49, change “Anhydrous” to -- anhydrous --.
Column 9

Table II, No. 14), after “4.1” insert -- Van --;
No. 20; change “10196” to -- 10/90 --.
Column 10

Line 20, add at the end of the formula: -- /(t1-to) --.
Column 11

Table III, last line, change “4.41' to -- 1.41 --.
Column 12

Line 25, change "3,4-” to -- 3,4-b --.
Column 13

Table VII, No. 9) after “1.09” insert -- 15/85 DMP-Van --; No. 10), change “1.03 to -1.08 --; No. 11), change “1.03” to -- 1.08 --.
Column 17

Table XI, last line, change “8:5” to -- 8.5 --.
Column 18, Table XIII

Line 51, change “65=” to -- 6.5 --.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION
PATENT NO.
DATED

: 5,874,005
: February 23, 1999

Page 2 of 2

INVENTOR(S) : Daniel Armstrong
It is certified that error appears in the above-identified patent and that said Letters Patent is
hereby corrected as shown below:
Column 20

Table XV, No. 5, change “AOC to -- AOC --.
Column 25

Table XVII, on line of Glutamic acid, change “5.7” to -- -5.7 --; on line of Suprofen,
change “-6.7” to -- -8.7 --; on line of +-Dibromohydrocinnamic acid, change “-7.6’ to
-- -7.8 --.

Column 27 Table XIX

Line 31, change “Riatocetin” to -- Ristocetin --;
Line 40, change “Riatocetin” to -- Ristocetin --.
Column 29, Table XXI

Line 2, change “1.9” to -- 4.9 --;
Line 11, change “8.3’ to -- -8.3 -:
Line 12, change “40.0” to -- 40.6 --;
Line 16, change “7.6’ to -- -7.6 --.
Column 31 Table XXIII

Line 14, delete “4-Benzyl-2-”
This Certificate of Correction Supersedes the Certificate issued January 1, 2002.

Signed and Sealed this
Fourteenth Day of January, 2003

JAMES E ROGAN

Director of the United States Patent and Trademark Office

